So, come Friday at 8 am EDT, will the New Merck post a German Merck-Serono style disappointment, an Eli Lilly-stlye yawner, or a Novartis-style winner/suprisingly strong Q2 2011?
We'll see -- and live blog it here -- and you may listen in, right here:
. . . .Merck will hold its second-quarter 2011 sales and earnings conference call with institutional investors and analysts at 8 a.m. EDT on Friday, July 29. During the call, Kenneth C. Frazier, president and chief executive officer, Peter N. Kellogg, executive vice president and chief financial officer, and Adam H. Schechter, president, Global Human Health, will provide an overview of Merck’s financial performance for the quarter. . . .
WHAT'S EXPECTED: Analysts surveyed by FactSet forecast earnings per share of 95 cents and sales of $11.81 billion. . . .
See you Friday.
No comments:
Post a Comment